Europe’s startup ecosystem has grown over the past decade, with several companies reaching the billion-dollar mark. Atomico’s State of European Tech report states that 11 ecosystems without such companies in 2015 now have at least one.
Dealroom data shows that Europe has 571 unicorns, including 22 new ones in 2024 – 37 of them have reached valuations above $10B.
Total funding in the continent has also multiplied by 10 over the last decade, increasing from $43B to $426B. Although investment levels declined after 2021, projections for 2025 estimate $47B in funding, a 20 per cent rise from 2020. The number of early-stage startups has also increased from 8,000 in 2015 to over 35,000, while growth-stage companies now exceed over 3,400.
According to Dealroom, in Q1 2025, European startups have secured $15.8B through nearly 1,600 funding rounds. From AI and fintech to clean energy and biotech, startups have attracted large amounts of funding, signalling investor confidence in Europe’s potential to lead in technology, health, and sustainability.
With this influx of funding, many of these high-growth companies are rapidly expanding their teams, offering exciting opportunities for top talent. Today, we look at the biggest funding rounds that have made headlines and most of them are hiring as well.
VistaJet
Founder/s: Thomas Flohr
HQ: Malta
Funding raised: $600M
Hiring: Yes, apply here
VistaJet is a business aviation company that operates a fleet of silver and red jets, serving corporations, governments, and private clients in 187 countries. Founded in 2004, the company introduced a business model allowing customers access to its fleet while only paying for the hours they fly, without the risks of aircraft ownership.
The company’s signature programme membership offers clients a subscription for flight hours with guaranteed access to VistaJet’s fleet. VistaJet is part of Vista, a private aviation ecosystem offering asset-free solutions across business aviation.
Isomorphic Labs
Founder/s: Sir Demis Hassabis
HQ: London, UK
Funding raised: $600M (nearly €555.44M) in first external funding
Hiring: Yes, apply here
Isomorphic Labs uses AI to change the drug design process from basic principles. Its technology allows researchers to explore new chemical possibilities and tackle difficult targets more quickly and accurately.
The company has developed advanced AI models that work together as a comprehensive drug design engine, aiming to change how drugs are created and impact medicine.
Isomorphic Labs is a spin-off from Alphabet’s AI research division, Google DeepMind, with many team members involved in developing AlphaFold, an AI model for predicting protein structures. The company applies DeepMind’s AI software, including AlphaFold, to drug discovery.
Verdiva Bio
Founder/s: Khurem Farooq (CEO)
HQ: London, UK
Funding raised: €398.4M in an oversubscribed Series A round
Hiring: Currently not hiring
Verdiva Bio is focused on creating next-generation therapies to help people with obesity and related health issues achieve better outcomes with more patient-friendly treatments.
The company’s leading therapy, VRB-101, is an oral GLP-1 peptide in clinical development. It has shown strong efficacy in a Phase 1 study in Australia and is suitable for once-weekly dosing.
Verdiva is also developing various amylin molecules and other programmes which aim for improved effectiveness, better tolerability, and healthier weight loss.
Amboss
Founder/s: Dr. Madjid Salimi, Benedikt Hochkirchen
HQ: Berlin, Germany
Funding raised: Closed a €240M financing round
Hiring: Yes, apply here
AMBOSS is a medical technology company that provides medical knowledge for students and clinicians. Its platform offers an interactive library and question bank for study and exam preparation, while clinicians rely on evidence-based recommendations for clinical decision-making.
The platform integrates medical expertise and technology to support clinical decision-making. It provides diagnostic and treatment recommendations based on current guidelines, helping clinicians save time and reduce errors.
Neko Health
Founder/s: Hjalmar Nilsonne, Daniel Ek
HQ: Stockholm, Sweden
Funding raised: $260M (nearly €250M) in a Series B funding round
Hiring: Yes, apply here
Neko Health aims to develop a healthcare system that can help individuals maintain their health via early identification and preventative actions. The company has developed a new medical scanning technology concept for broad and non-invasive health data collection that is fast, convenient and affordable.
Auro Travel
Founder/s: Zaryn Dentzel, Alejandro Betancourt López, Hugo Arevalo
HQ: Madrid, Spain
Funding raised: €220M
Hiring: Currently not hiring
Auro Travel claims to operate the largest VTC (Vehicles with Driver) fleet in the country with its app and technology. Its main goal is to modernise fleet management for passenger transportation.
The company uses technology in GPS tracking, real-time traffic monitoring, LPG engine conversion, vehicle maintenance, driving indicators, and driver communication. This approach allows for detailed service control and the provision of operational KPIs to clients, enabling them to monitor travel data and environmental impact.
Windward Bio
Founder/s: Luca Santarelli
HQ: –
Funding raised: $200M in Series A round
Hiring: Currently not hiring
Windward Bio is a clinical-stage drug development company focused on improving outcomes for individuals with advanced immunological diseases, initially targeting severe respiratory conditions.
The company is advancing a thymic stromal lymphopoietin (TSLP) monoclonal antibody into phase 2 development and creating bispecific programmes for immunological diseases.
TravelPerk
Founder/s: Avi Meir, Javier Suarez
HQ: Barcelona, Spain
Funding raised: $200M (nearly €191.75M) in an oversubscribed Series E round
Hiring: Yes, apply here
TravelPerk is a SaaS platform that aims to transform business travel with its all-in-one solution. It claims to provide travellers with freedom and company control, saving time, money, and hassle. The platform aims to streamline business travel management globally.
Synthesia
Founder/s: Steffen Tjerrild, Prof. Lourdes Agapito, Prof. Matthias Niessner, Victor Riparbelli
HQ: London, UK
Funding raised: $180M (nearly €174.5M) in Series D round
Hiring: Yes, apply here
Synthesia’s platform allows any enterprise user, from HR managers to marketers, to easily create high-quality instructional videos featuring stock or custom AI avatars.
The company claims that its clients report up to 95 per cent savings in production time. This amounts to thousands of dollars in reduced costs and increased engagement from their employees and customers.
Over 1 million users across 60,000 businesses use Synthesia’s technology to create training, instructional, and product marketing videos in minutes.
Ori Industries
Founder/s: Mahdi Yahya
HQ: London, UK
Funding raised: Undisclosed
Hiring: Yes, apply here
Ori is developing AI infrastructure to support teams in advancing technology. The company provides end-to-end AI solutions, combining GPU computing with a flexible software layer to optimise resources.
The company aims to enable teams to access and deploy the infrastructure needed to train, serve, and scale models, facilitating AI innovation and collaboration between software and hardware.
Quantexa
Founder/s: Vishal Marria
HQ: London, UK
Funding raised: €161M in Series F round
Hiring: Yes, apply here
Quantexa is an AI, data, and analytics software company focused on Decision Intelligence. The company’s platform helps organisations make operational decisions by unifying data and uncovering hidden risks and opportunities. It addresses challenges in data management, customer intelligence, KYC, financial crime, fraud, and security.
Quantexa’s platform improves operational performance with accuracy and faster analytical model resolution compared to traditional methods.
Solaris
Founder/s: Carsten Höltkemeyer (CEO)
HQ: Berlin, Germany
Funding raised: €140M in Series G round
Hiring: Yes, apply here
Solaris provides a banking-as-a-service platform that allows businesses to integrate financial services into new contexts. With a German banking license, it handles regulatory and technological challenges, ensuring compliance with standards such as DORA, PSD2, and deposit protection. The platform supports companies of all sizes in launching banking products efficiently and securely.
OrganOx
Founder/s: Craig Marshall
HQ: Oxford, England
Funding raised: $142M in primary and secondary equity financing
Hiring: Currently not hiring
OrganOx develops technologies for organ failure treatment. Its normothermic machine perfusion platform, the OrganOx metra, is approved in multiple regions, including the US, Europe, Canada, and Australia.
The device has been used in over 5,000 liver transplants, maintaining donor livers in a metabolically active state outside the body for functional assessment before transplantation, expanding the pool of available organs.
Neura Robotics
Founder/s: David Reger
HQ: Metzingen, Germany
Funding raised: €120M in a Series B round
Hiring: Yes, apply here
NEURA Robotics has developed collaborative robots (cobots) with advanced sensory capabilities, enabling them to see, hear, and perceive touch. These robots use reflexive sensory processing for autonomous and predictive actions.
The company developed MAiRA, the world’s first cognitive cobot combining AI and robotics, capable of autonomous operation and interaction with humans.
NEURA Robotics is developing robots intended for collaboration with humans in industries like manufacturing, logistics, and healthcare.
XOCEAN
Founder/s: James Ives
HQ: Dundalk, Ireland
Funding raised: €115M in funding
Hiring: Yes, apply here
XOCEAN has developed a fleet of Uncrewed Surface Vessels (USVs) to provide offshore geophysical data solutions. These USVs integrate advanced sensors, real-time communications, and post-processing capabilities to offer a flexible and cost-effective alternative to traditional methods.
With a low-carbon fleet that emits only 0.1 per cent of the CO2 of manned vessels, XOCEAN aims to reduce carbon emissions over the next decade and is also focused on achieving 30x gender diversity within its team.
Tines
Founder/s: Eoin Hinchy, Thomas Kinsella
HQ: Dublin, Ireland
Funding raised: $125M (nearly €120M) in a Series C round
Hiring: Yes, apply here
Tines provides a workflow platform empowering every team member with robust automation and orchestration capabilities.
Recently, the company launched native AI features and Workbench, a generative AI chat interface that enables users to query, gather, and analyse information, take real-time action on data across applications, and determine the next steps.
As per the company’s claims, the number of automated actions within the Tines platform has more than tripled over the past year, exceeding one billion tasks automated every week.
Marvel Fusion
Founder/s: Moritz von der Linden
HQ: Munich, Germany
Funding raised: Extended its Series B round by €50M, bringing the total to €113M
Hiring: Yes, apply here
Marvel Fusion is developing a new fusion energy technology that leverages advances in laser and nanoscience to increase the probability of fusion.
The company aims to create a safe, reliable, and scalable energy source. It is focused on solving complex technological challenges and advancing fusion energy as a sustainable power solution.
CeQur
Founder/s: Bradley Paddock
HQ: Horw, Switzerland
Funding raised: $120M (nearly €116.4M) in funding
Hiring: Yes, apply here
CeQur is commercialising advanced, simple-to-use insulin delivery devices that make it easier for people living with diabetes to adhere to therapy and stay in control of their disease.
The company’s product, CeQur Simplicity, is a simple, four-day wearable Insulin Delivery Device for convenient, injection-free bolus dosing.
One CeQur Simplicity patch holds up to 200 units of rapid-acting insulin administered in two-unit increments and replaces, on average, twelve daily mealtime injections over four days.
01
These are the top UK-based PR agencies for startups and scale-ups in 2025